China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 14 October 2021, New Drug Application of the Group’s innovative drug Tildrakizumab solution for injection (the “Product”) has been accepted by the National Medical Products Administration of the People’s Republic of China.
The Product is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and has been approved for marketing in the U.S., Australia, European Union, Switzerland, Japan and Canada.